Menu
Washingtoner
  • Home
  • Health
  • Boeing
  • Daryl Guberman
  • Aerospace
  • Business
  • Technology
  • Books
  • Lifestyle
Washingtoner

Global Addiction Treatment Market to Surpass US$ 12,210.0 Million by 2028, Says Coherent Market Insights
Washingtoner/10152734

Trending...
  • Joseph Nybyk aka Neibich of Gilbert, Arizona
  • Spokane: SPD is Seeking Public's Assistance in Locating Dangerous Offender
  • City of Tacoma Observes Memorial Day on May 25
SEATTLE, Jan. 28, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global addiction treatment market is estimated to be valued at US$ 8,297.0 million in 2021 and is expected to exhibit a CAGR of 5.3% over the forecast period (2021-2028).

Key Trends and Analysis of the Global Addiction Treatment Market:


Key trends in the market include the rising prevalence of addicted population, increasing product approvals and launches, initiatives by various organizations towards de-addiction, and increasing collaborations, partnerships, mergers and acquisitions among key players. These key trends are expected to aid in the growth of the addiction treatment market.

For instance, in May 2018, US WorldMeds LLC a Kentucky-based specialty pharmaceutical company received the U.S. Food and Drug Administration approval for its novel drug lofexidine hydrochloride (Lucemyra) for mitigation of opioid withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults.

Moreover, various government and private organizations are taking initiatives to spread awareness about nicotine de-addiction, which supports addicted person to quit smoking with the help of smoking cessation products. For instance, in 2017, the Public Health England launched US$ 1.3 million smoking cessation campaign to increase awareness to quit smoking.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4853

Furthermore, key players operating in the global addiction treatment market are focusing on adoption of inorganic growth strategies such as acquisitions, mergers, partnerships, and collaborations, in order to strengthen their market presence in the global market. For instance, in August 2018, Elite Laboratories Inc. a specialty pharmaceutical company partnered with Glenmark Pharmaceuticals Ltd. a leading integrated research-based, global pharmaceutical company for distribution of its recently U.S. FDA approved methadone hydrochloride 5 mg and 10 mg tablets. As per the partnership Glenmark Pharmaceuticals, Inc., will sell and distribute methadone in the U.S. for Elite and Elite will receive manufacturing license for methadone.

More on Washingtoner
  • City to Establish Spokane Urban Native Advisory Council
  • Christian Apocalyptic Thriller Explores Biblical Prophecy, Global Technology, & the Rise of the Ant
  • The Hidden Price Of Lost Property In UK Schools
  • Milton Collier, CEO & President of Freight Broker 911, Eliminates the #1 Barrier to Entry in Logistics: Announces 100% Free Freight Broker Training
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP

Additionally, in March 2018, GlaxoSmithKline plc.(GSK) entered into an agreement to buyout Novartis AG a Switzerland based global healthcare company stake in the Consumer Healthcare joint venture. According to this agreement, Novartis AG divested its 36.5% stake in a consumer healthcare Joint Venture for total deal value of US$ 13 billion. This joint venture allows GSK to add Novartis' Nicotinell nicotine patch product into its portfolio. This product relieves and prevent cravings and withdrawl symptoms of nicotine. These factors are expected to boost growth of the addiction treatment market over the forecast period.

Key Market Takeaways:

The global addiction treatment market is expected to exhibit a CAGR of 5.3% over the forecast period, owing to increase in number of product approvals. For instance, in 2017, Akorn, Inc. and American generic pharmaceuticals manufacturer received the U.S. Food and Drug Administration (FDA) approval for generic versions of Methadone Hydrochloride Injection USP, 200 mg/20 mL (10 mg/mL) multi-dose vial. It is use treatment of opioid dependence. This generic drug is approved for temporary treatment of patients with opioid dependence, who are unable to take oral medication.

Among drug type, nicotine replacement therapies segment accounted for the largest market share in forecast period, owing to rising product launches. In 2018, Epic Pharma, LLC a generic pharmaceutical company launched Methadone Hydrochloride Tablets, USP in 5mg and 10mg strengths, the generic equivalent of Dolophine. Methadone Hydrochloride Tablets, USP are indicated for the treatment of opioid addiction as well as for management of pain indication.

Key players operating in the global addiction treatment market include Alkremes Plc., Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals, Titan Pharmaceuticals, Inc., Pfizer, Inc., GlaxoSmithKline plc. Johnson & Johnson, Perrigo Company plc., Cipla Limited, Hikma Pharmaceuticals Plc., Dr. Reddy's Laboratories Limited, Indivior Inc., and Mylan N.V.

Request for Customization @
https://www.coherentmarketinsights.com/insight/request-customization/4853

More on Washingtoner
  • AI Velocity Trading Launches Institutional-Grade Algorithmic Engine for Retail Investors
  • Speaker and Certified Coach Syrena N. Williams Debuts Powerful New Book on Healing, Identity, and Wholeness
  • Spokane: SPD Releases Name of Officer Involved in OIS on North Cincinnati
  • Spokane: Civics 101: How To Engage With Council Workshop
  • Bestselling author Diana Colleen Explores the Psychology of Billionaires in New Podcast Interview

Detailed Market Segmentation:

Global Addiction Treatment Market, By Drug Type:
  • Opioid Addiction
    • Methadone
    • Buprenorphine
    • Naltrexone
  • Alcohol Addiction
    • Acamprosate
    • Disulfiram
    • Naltrexone
    • Others
  • Nicotine Replacement Therapies
    • Nicotine Gums
    • Nicotine Patches
    • Nicotine Lozenges
    • Nicotine Spray
    • Nicotine Inhaler
    • Nicotine Sublingual Tablets
  • Non-Nicotine Medication
    • Varenicline
    • Bupropion (Zyban)

Global Addiction Treatment Market, By Region:
  • North America
    • By Country:
      • U.S.
      • Canada
  • Europe
    • By Country:
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country:
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East & Africa
    • By Country:
      • GCC Countries
      • Israel
      • South Africa
      • Rest of Middle East & Africa

Buy this Complete Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/4853

About Us:

Coherent Market Insights
is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:

Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US
: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: [email protected]
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter

SOURCE Coherent Market Insights
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Tacoma: Applicants Sought for the Transportation Commission
  • Tacoma: Update Homicide Investigation – Arrest – 1200 block of South M Street
  • Tacoma: Homicide Investigation – 1200 block of South M Street
  • Buzzblender Announces Launch of Simple Hotel Mode for Android and Upcoming Video Wall Support for Samsung Professional Displays
  • How Strategic WooCommerce Development and Digital Marketing Helped a Fashion Ecommerce Business Increase Revenue by 3X
  • VIV Welcomes Residents to St. Petersburg's EDGE District
  • Evocative Joins the Independent Data Centre Network (IDCN) as Primary USA Operator
  • Medical Experts Highlight the Importance of Second Opinions in Death Investigations
  • Joseph Nybyk aka Neibich of Gilbert, Arizona
  • Omnitronics Unveils 100% Software omniGateDMR and omniGateP25 RoIP Gateways
  • KRE PRIME Launches Adaptive Convertible Jumpsuit
  • USA Med Bed Helping Home Care Patients with Refurbished Hill Rom Hospital Beds
  • Sobreseimiento de Nicolás dos Santos y Jorge Méndez expone demandas millonarias a Paraguay y boicot a la Hidrovía
  • CAPHRA warns Southeast Asia not to repeat Australia's nicotine policy failure
  • Milo3D.ai Launches Free AI 3D Model Generator That Turns Text and Images Into Game-Ready 3D Assets in Seconds
  • UK Financial Ltd Executes 100% Success Rate on All ERC-3643 Transfers to Coin Holders of MayaCat Regulated Security Token and Maya Preferred PRA
  • City of Tacoma Observes Memorial Day on May 25
  • Blank Space: The Unofficial Taylor Swift Tribute Brings Eras Tour Magic To Cities Across America
  • Love Must Be the Guide: Live Good Shares a Message of Humanity, Compassion and Hope
  • D.R. Crotzer Announces A New Science Fiction Book Series Exploring Life Energy, Dreams, and the Mystery of Existence
_catLbl0 _catLbl1

Popular on Washingtoner

  • Altruvest and Financial Executives International Canada Announce Strategic Partnership to Strengthen Nonprofit Boards Across Canada - 108
  • Umbrella Becomes First FinOps Platform to Support AWS Billing Transfer Onboarding
  • Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
  • Applicants Sought for the Tacoma Creates Advisory Board
  • Spokane AI Expert Adam Chronister to Discuss Authority Engineering at AI Roundtable Event
  • RAS AP Consulting Advances to RFP Stage in Heidelberg Materials' SAP Vendor & Customer Master Data Modernization Initiative
  • Resident Inspect Joins Property Meld Nexus Network with API Integration
  • Spokane Police arrest male for threats against “The Villages” and Mar-A-Lago
  • Spokane: SPD Air Support Unit Continues to be a Vital Tool for the Department
  • $10 Million Annual Revenue Merger, Profitable Partner in AI Powered Specialty Automotive Sales Projected to Scale Above $200M: Stock Symbol: NWPG

Similar on Washingtoner

  • Zenylitics Announces Leadership Transition to Continue Accelerated Growth
  • Wellness Technology Distributor Helping People Set Up Wellness Center Businesses
  • Milton Collier, CEO & President of Freight Broker 911, Eliminates the #1 Barrier to Entry in Logistics: Announces 100% Free Freight Broker Training
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
  • KRE PRIME Launches Adaptive Convertible Jumpsuit
  • Sobreseimiento de Nicolás dos Santos y Jorge Méndez expone demandas millonarias a Paraguay y boicot a la Hidrovía
  • UK Financial Ltd Executes 100% Success Rate on All ERC-3643 Transfers to Coin Holders of MayaCat Regulated Security Token and Maya Preferred PRA
  • Global.ai Appoints Freedomtech Solutions as Specialist Partner for Agentic AI
  • Triple-Digit Growth, OTCQX Market Upgrade and a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation: Stock Symbol: CDIX
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute